Journal
LANCET NEUROLOGY
Volume 12, Issue 5, Pages 435-442Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(13)70061-9
Keywords
-
Categories
Funding
- NIH
- Muscular Dystrophy Association
- Neuromuscular Research Fund
- Insmed
- Knopp
- Cytokinetics
- Biogen Idec
- ISIS
- Genzyme
- GlaxoSmithKline
- Ultragenyx
- Sanofi
- ALSA
- MDA
- Biogen
- Psyadon Pharmaceuticals
- Isis Pharmaceuticals
- Tau consortium
- Mallinckrodt Foundation
- Cure PSP
- Washington University Hope Center
- ALS
- Johns Hopkins Packard Center
- Washington University ICTS
- The ALS Association
- National Institute of Neurological Disorders and Stroke (NIH) [K08NS074194, R01NS078398]
- Washington University Institute of Clinical and Translational Sciences [UL1 TR000448]
- National Center for Advancing Translational Sciences (NIH)
- Grifols
- Gamunex
Ask authors/readers for more resources
Background Mutations in SOD1 cause 13% of familial amyotrophic lateral sclerosis. In the SOD1 Gly93Ala rat model of amyotrophic lateral sclerosis, the antisense oligonucleotide ISIS 333611 delivered to CSF decreased SOD1 mRNA and protein concentrations in spinal cord tissue and prolonged survival. We aimed to assess the safety, tolerability, and pharmacokinetics of ISIS 333611 after intrathecal administration in patients with SOD1-related familial amyotrophic lateral sclerosis. Methods In this randomised, placebo-controlled, phase 1 trial, we delivered ISIS 333611 by intrathecal infusion using an external pump over 11.5 h at increasing doses (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg) to four cohorts of eight patients with SOD1-positive amyotrophic lateral sclerosis (six patients assigned to ISIS 333611, two to placebo in each cohort). We did the randomisation with a web-based system, assigning patients in blocks of four. Patients and investigators were masked to treatment assignment. Participants were allowed to re-enrol in subsequent cohorts. Our primary objective was to assess the safety and tolerability of ISIS 333611. Assessments were done during infusion and over 28 days after infusion. This study was registered with Clinicaltrials.gov, number NCT01041222. Findings Seven of eight (88%) patients in the placebo group versus 20 of 24 (83%) in the ISIS 333611 group had adverse events. The most common events were post-lumbar puncture syndrome (3/8 [38%] vs 8/24 [33%]), back pain (4/8 [50%] vs 4/24 [17%]), and nausea (0/8 [0%] vs 3/24 [13%]). We recorded no dose-limiting toxic effects or any safety or tolerability concerns related to ISIS 333611. No serious adverse events occurred in patients given ISIS 333611. Re-enrolment and re-treatment were also well tolerated. Interpretation This trial is the first clinical study of intrathecal delivery of an antisense oligonucleotide. ISIS 333611 was well tolerated when administered as an intrathecal infusion. Antisense oligonucleotides delivered to the CNS might be a feasible treatment for neurological disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available